NasdaqGM:LGNDPharmaceuticals
Ligand Pharmaceuticals (LGND) Returns To Trailing Profitability Challenging Cautious Earnings Narratives
Ligand Pharmaceuticals (LGND) opened Q1 2026 with revenue of US$51.7 million and a basic EPS loss of US$0.67, alongside a net loss of US$13.3 million. The company reported revenue of US$45.3 million and a basic EPS loss of US$2.21 in Q1 2025, compared with US$51.7 million and a basic EPS loss of US$0.67 in Q1 2026. Trailing twelve month EPS stood at US$7.87 on net income of US$153.6 million. For investors, the combination of a quarterly loss and a profitable trailing year encourages a closer...